Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Leukemia. 2010 Jun 10;24(8):1437–1444. doi: 10.1038/leu.2010.132

Figure 1. Sorafenib N-oxide is a potent FLT3 inhibitor.

Figure 1

A. Standard curve generated as described previously(17), from western blot of TF-ITD cells in plasma exposed for one hour to increasing concentrations of sorafenib. B. Standard curve generated with sorafenib N-oxide in plasma.